Literature DB >> 19448530

Molecular genotyping of hemophilia A in Saudi Arabia: report of 2 novel mutations.

Tarek M Owaidah1, Hala Aba Alkhail, Hazzaa Al Zahrani, Abdulrahaman Al Musa, Mahasen Al Saleh, Mahmoud Abu Riash, Ali Alodaib, Khalid Abu Amero.   

Abstract

Different types of mutations have been reported in patients with hemophilia A. Although about half of all severe factor VIII deficiencies are caused by gene rearrangements (inversions) involving intron 22 in F8, other mutations such as point mutation, large deletions and insertions had been reported. We report the result of the first molecular testing for or F8 mutations from Saudi Arabia. A cohort of 22 men with hemophilia A was studied for F8 mutations. All patients were tested for factor VIII coagulant activity and inhibitors. Peripheral blood samples were used for DNA extraction followed by PCR detection of intron 22 inversion and all samples tested negative were screened for other F8 mutations. The patient's age ranged between 4 and 37 years. All patients except two siblings had severe hemophilia A. Only two patients out of 22 developed inhibitors with no obvious relation to the genotype. F8 Intron 22 inversion was detected in 10 patients (50%) of severe cases. Additionally, five point mutations and one deletion/insertion involving different exons were detected. All identified mutations were associated with severe phenotype except for one, which was associated with mild phenotype of hemophilia. This is the first report of molecular genotype of hemophilia A in the Saudi population and one of the few for Arab population. We had confirmed the incidence of Inversion 22 in severe hemophilia. We are reporting two novel mutations in F8, which can be used for carrier detection and prenatal genetic diagnosis (PGD).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19448530     DOI: 10.1097/MBC.0b013e328329e456

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.

Authors:  Tarek Owaidah; Abdulkareem Al Momen; Hazzaa Alzahrani; Abdulrahman Almusa; Fawaz Alkasim; Ahmed Tarawah; Randa Al Nouno; Fatima Al Batniji; Fahad Alothman; Ali Alomari; Saud Abu-Herbish; Mahmoud Abu-Riash; Khawar Siddiqui; Mansor Ahmed; S Y Mohamed; Mahasen Saleh
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

2.  Molecular Analysis of Factor VIII and Factor IX Genes in Hemophilia Patients: Identification of Novel Mutations and Molecular Dynamics Studies.

Authors:  Faisal A Al-Allaf; Mohiuddin M Taher; Zainularifeen Abduljaleel; Abdellatif Bouazzaoui; Mohammed Athar; Neda M Bogari; Halah A Abalkhail; Tarek Ma Owaidah
Journal:  J Clin Med Res       Date:  2017-02-21

3.  Identification of the Intron 22 and Intron 1 Inversions of the Factor VIII Gene in Iraqi Kurdish Patients With Hemophilia A.

Authors:  Aveen M Raouf Abdulqader; Ali Ibrahim Mohammed; Shwan Rachid; Peyman Ghoraishizadeh; Sarwar Noori Mahmood
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

4.  First report of molecular diagnosis of Tunisian hemophiliacs A: identification of 8 novel causative mutations.

Authors:  Hejer Elmahmoudi; Houssein Khodjet-el-khil; Edvard Wigren; Asma Jlizi; Kaouther Zahra; Dorothé Pellechia; Christine Vinciguerra; Balkis Meddeb; Amel Ben Ammar Elggaaied; Emna Gouider
Journal:  Diagn Pathol       Date:  2012-08-10       Impact factor: 2.644

5.  Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services.

Authors:  Raida Oudat; Muna Al-Maharmeh; Rasha Al-Ghrayeb; Tunia Ogeilat; Maher Kh Mustafa
Journal:  Med Arch       Date:  2020-06

6.  Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?

Authors:  Laila M Sherief; Osama A Gaber; Hala Mosaad Youssef; Hanan S Sherbiny; Wesam A Mokhtar; Asmaa A A Ali; Naglaa M Kamal; Yehia H Abdel Maksoud
Journal:  Ital J Pediatr       Date:  2020-09-14       Impact factor: 2.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.